PTGS2 and neoplasm: Mice which experienced CR after triple combination therapy (S+P + COX2) were completely immune to the regrowth of MC38 colon cancer cells and remained tumor-free, whereas mice which experienced CR after dual combination therapy (S+COX2) were not protected from MC38 tumor cell rechallenge (figure 7J).